Visual Abstract
Background: With OS’s FDA approval in September 2019, this study sought to provide real-world evidence on its effectiveness in a cohort of early users.
Methods: Claims and lab result data were used to identify T2D patients who initiated OS between 09/20/19 - 10/31/20 (first claim date set as index). Selected patients had ≥1 HbA1c result within both ≤3 months pre- and ≥3 months post-index and ≥ 12 months pre-index health plan eligibility. Study groups included: all patients, patients persistent on OS (those with a OS prescription within 1.5 times of days supply dispensed overlapping/in proximity to most recent post-index HbA1c), GLP-1 naïve patients, and patients with a pre-index HbA1c >9%.
Results: Of the 323 individuals with T2D initiating OS, 42.4% were female with a mean age of 55 years and 77% were GLP-1 naive. Mean HbA1c was significantly reduced in all patients (-0.9%) and subgroups (all p<0.001, Figure 1). Percent of patients with HbA1c <7% increased across all groups, ranging from a 24-28% increase compared to baseline. Persistent patients also achieved a 0.9% mean HbA1c reduction, with similar or greater reduction across subgroups when compared to all patients.
Conclusions: OS initiation was associated with a significant reduction in HbA1c and increase in HbA1c goal attainment in real-world practice in this preliminary cohort.
N. Shivappa: Other Relationship; Self; Novo Nordisk. C. Swift: Employee; Self; Novo Nordisk Inc. J. Noone: Employee; Self; Novo Nordisk Inc. S. Du: None. M. Radin: Employee; Self; Novo Nordisk Inc. C. Gamble: Employee; Self; Novo Nordisk Inc. H. Tan: Other Relationship; Self; HealthCore. V. Willey: Employee; Self; HealthCore.
